Cereno Scientific
Cereno Scientific strengthens R&D with recruitment of Medical Director
“I am pleased to welcome Tatiane to the team as we enter a significant phase for Cereno with intensified operations in our preclinical and clinical development programs. Tatiane has been part of our team in a consultancy capacity during the last two years and will in her new role as Medical Director be a key team member in Cereno’s R&D team for our scientific, medical, and clinical activities as we advance our development programs,” said Sten R. Sörensen, CEO at Cereno Scientific.
Tatiane Abreu Dall’Agnol is a medical doctor with nearly a decade of clinical experience. She has previously also worked as a life science consultant advising biotech companies on drug development strategy and analysis; and gained experience in business development and competitive intelligence at Pieris Pharmaceuticals. Tatiane has a medical degree from the Universidade Positivo, Curitiba, PR, Brazil, and an M.Sc. in Business Creation and Entrepreneurship in Biomedicine from the University of Gothenburg, Sweden.
For further information, please contact:
Tove Bergenholt, Director IR & Communications
Email: tove.bergenholt@cerenoscientific.com
Phone: +46 732-366 246
Sten R. Sörensen, CEO
Email: sten.sorensen@cerenoscientific.com
Phone: +46 73-374 03 74
About Cereno Scientific AB
Cereno Scientific develops innovative treatments for common and rare cardiovascular disease. The lead drug candidate, CS1, is a HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final study results that are expected in Q2 2024. After requests by investigators in the Phase II study, a “compassionate use” application for CS1 is currently being pursued. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Investigational drug CS014 is a HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in several preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding, which also has been recognized in the medical community. CS585 was in-licensed from the University of Michigan in 2023. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.
Datum | 2024-01-12, kl 08:30 |
Källa | Cision |
![](https://static.allaaktier.se/ads/hand-waving-2.png)